Idenix Pharmaceuticals LLC
99Patents
65Active
99Granted
52Portfolio score
Filing activity: Feb 26, 2001 → Jun 13, 2019 · 20 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7105493B2 | Methods and compositions for treating flaviviruses and pestiviruses | Emerging Cross-Sectional Technologies | 179 | Expired |
| US6914054B2 | Methods and compositions for treating hepatitis C virus | Physics | 168 | Expired |
| US7608597B2 | Methods and compositions for treating hepatitis C virus | Physics | 153 | Expired |
| US6812219B2 | Methods and compositions for treating flaviviruses and pestiviruses | Emerging Cross-Sectional Technologies | 147 | Expired |
| US7608600B2 | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | Chemistry; Metallurgy | 144 | Expired |
| US7148206B2 | Methods and compositions for treating flaviviruses and pestiviruses | Emerging Cross-Sectional Technologies | 126 | Expired |
| US7163929B2 | Methods and compositions for treating flaviviruses and pestiviruses | Emerging Cross-Sectional Technologies | 123 | Expired |
| US7169766B2 | Methods and compositions for treating hepatitis C virus | Physics | 101 | Expired |
| US7365057B2 | Modified 2′ and 3′-nucleoside prodrugs for treating Flavivridae infections | Chemistry; Metallurgy | 95 | Expired |
| US7635689B2 | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | Chemistry; Metallurgy | 93 | Expired |
| US7157441B2 | Methods and compositions for treating hepatitis C virus | Physics | 93 | Expired |
| US6787526B1 | Methods of treating hepatitis delta virus infection with &bgr;-L-2′-deoxy-nucleosides | Chemistry; Metallurgy | 81 | Expired |
| US7951789B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | Chemistry; Metallurgy | 69 | Active |
| US7625875B2 | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | Human Necessities | 67 | Expired |
| US7547704B2 | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | Chemistry; Metallurgy | 64 | Expired |
| US7456155B2 | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | Human Necessities | 64 | Expired |
| US7192936B2 | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | Chemistry; Metallurgy | 61 | Expired |
| US6566344B1 | &bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B | Chemistry; Metallurgy | 61 | Expired |
| US7138376B2 | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides | Chemistry; Metallurgy | 61 | Expired |
| US7902202B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | Chemistry; Metallurgy | 60 | Active |
| US7384924B2 | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | Chemistry; Metallurgy | 59 | Expired |
| US7582618B2 | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | Human Necessities | 58 | Active |
| US9211300B2 | 4′-fluoro nucleosides for the treatment of HCV | Chemistry; Metallurgy | 55 | Active |
| US7662798B2 | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | Human Necessities | 55 | Expired |
| US7824851B2 | 2′-branched nucleosides and Flaviviridae mutation | Emerging Cross-Sectional Technologies | 54 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.